SIRPA and cancer: In line with this, when activated, bone marrow-derived macrophage (BMDMs) obtained from Sirpα−/− mice displayed a strong capacity to phagocytize CD47-expressing MC38 cancer cells, whereas BMDMs from WT mice failed to engulf cancer cells under the same treatment (Supplementary Fig. 1a).